Login to Your Account

Much-needed optimism coming to AML space

By Jennifer Boggs
Managing Editor

Monday, December 5, 2016

SAN DIEGO – Despite four decades of clinical research in AML, the current standard-of-care induction therapy remains the 7 + 3 regimen, usually referring to seven days of cytarabine plus three days of daunorubicin, said Harry Erba.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription